MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era
- PMID: 34481845
- PMCID: PMC8608337
- DOI: 10.1053/j.gastro.2021.08.050
MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era
Abstract
Background & aims: The Model for End-Stage Liver Disease (MELD) has been established as a reliable indicator of short-term survival in patients with end-stage liver disease. The current version (MELDNa), consisting of the international normalized ratio and serum bilirubin, creatinine, and sodium, has been used to determine organ allocation priorities for liver transplantation in the United States. The objective was to optimize MELD further by taking into account additional variables and updating coefficients with contemporary data.
Methods: All candidates registered on the liver transplant wait list in the US national registry from January 2016 through December 2018 were included. Uni- and multivariable Cox models were developed to predict survival up to 90 days after wait list registration. Model fit was tested using the concordance statistic (C-statistic) and reclassification, and the Liver Simulated Allocation Model was used to estimate the impact of replacing MELDNa with the new model.
Results: The final multivariable model was characterized by (1) additional variables of female sex and serum albumin, (2) interactions between bilirubin and sodium and between albumin and creatinine, and (3) an upper bound for creatinine at 3.0 mg/dL. The final model (MELD 3.0) had better discrimination than MELDNa (C-statistic, 0.869 vs 0.862; P < .01). Importantly, MELD 3.0 correctly reclassified a net of 8.8% of decedents to a higher MELD tier, affording them a meaningfully higher chance of transplantation, particularly in women. In the Liver Simulated Allocation Model analysis, MELD 3.0 resulted in fewer wait list deaths compared to MELDNa (7788 vs 7850; P = .02).
Conclusion: MELD 3.0 affords more accurate mortality prediction in general than MELDNa and addresses determinants of wait list outcomes, including the sex disparity.
Keywords: End-Stage Liver Disease; Outcome Prediction; Wait List Mortality.
Copyright © 2021. Published by Elsevier Inc.
Figures
Comment in
-
MELD 3.0: One Small Step for Womankind or One Big Step for Everyone?Gastroenterology. 2022 May;162(6):1780-1781. doi: 10.1053/j.gastro.2021.09.014. Epub 2021 Sep 14. Gastroenterology. 2022. PMID: 34529990 No abstract available.
-
The Model for End-Stage Liver Disease 3.0: An Update Without Proven Accuracy.Gastroenterology. 2022 May;162(6):1781-1782. doi: 10.1053/j.gastro.2021.09.047. Epub 2021 Sep 25. Gastroenterology. 2022. PMID: 34582897 No abstract available.
-
Reply.Gastroenterology. 2022 May;162(6):1782-1783. doi: 10.1053/j.gastro.2022.01.017. Epub 2022 Jan 19. Gastroenterology. 2022. PMID: 35063443 No abstract available.
-
Letter to the Editor: Validation of MELD 3.0 scoring system in East Asian patients with cirrhosis awaiting liver transplantation.Liver Transpl. 2023 Nov 1;29(11):E36-E37. doi: 10.1097/LVT.0000000000000152. Epub 2023 Apr 11. Liver Transpl. 2023. PMID: 37036243 No abstract available.
-
Validation of MELD3.0 in 2 centers from different continents.Hepatol Commun. 2024 Jul 31;8(8):e0504. doi: 10.1097/HC9.0000000000000504. eCollection 2024 Aug 1. Hepatol Commun. 2024. PMID: 39082971 Free PMC article.
References
-
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology (Baltimore, Md). 2001;33(2):464–470. - PubMed
-
- Nagai S, Chau LC, Schilke RE, et al. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes. Gastroenterology. 2018;155(5):1451–1462.e1453. - PubMed
-
- Asrani SK, Jennings LW, Kim WR, et al. MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List. Hepatology (Baltimore, Md). 2020;71(5):1766–1774. - PubMed
-
- Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–96. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical